Blog

PARIS LA DÉFENSE, France, Oct. 13, 2025 /PRNewswire/ — Nexans announces that its Board of Directors has resolved to appoint Julien Hueber as the new Chief Executive Officer and to part ways with Christopher Guérin. These decisions will take effect immediately; Christopher will be available to Julien until October 31^st, 2025.

The Board of Directors wishes to create a new momentum to further optimize performance while executing the roadmap which was presented during the last Capital Market Day. The Appointments & Corporate Governance Committee has conducted a comprehensive process to propose a successor for the role of Chief Executive Officer, in line with its established succession plan approach and with the support of a leading executive search firm.

Julien Hueber, Executive Managing Director of Power Grid & Connect Europe, oversees a €2.6 billion business spanning 23 manufacturing plants. A member of Nexans’ Executive Committee since 2018, he joined the company in 2002. Julien brings extensive expertise in supply chain and procurement, as well as deep regional knowledge of Asia-Pacific, particularly China and South Korea, where he spent several years leading operations. He later headed Nexans’ global “Industrial Cables – Industry Solutions & Projects” business.

Jean Mouton, Chairman of the Board of Directors, stated: “Over the past 23 years, Julien has demonstrated exceptional leadership and a profound understanding of Nexans’ business, operating model, and culture. He combines a strategic vision for future technologies with a strong record of operational excellence, as evidenced by the remarkable acceleration of the PWR Grid & Connect Europe segment under his leadership. I have complete confidence in his ability to lead Nexans in this new phase of focused acceleration, in line with the goals announced during the last Capital Markets Day.”

The Board concluded that Julien Hueber’s extensive experience, proven leadership, and deep understanding of Nexans made him the ideal choice to lead the Company. His strong track record in shaping vision, defining strategy, and driving successful execution further reinforced this decision. The Board of Directors unanimously and enthusiastically endorsed his appointment.

The Board would like to express its deep gratitude to Christopher Guérin for his exceptional contribution to Nexans during his seven years as Chief Executive Officer. Beyond the strong financial results, Christopher has profoundly transformed Nexans into a focused leader in sustainable electrification, giving meaning and direction to its mission. He has brought innovation, responsibility, and simplicity to the heart of the company, while restoring confidence across teams worldwide. His leadership and passion have left a lasting mark on the Group and its people.

Jean Mouton, Chairman of the Board of Directors, said: “I would like to warmly thank Christopher for his remarkable commitment and his essential contribution to the transformation of Nexans. He has restored a sentiment of pride to be part of the Nexans family. We wish him every success in his future endeavours.”

About Nexans

Nexans is the global pure player in sustainable electrification, building the essential systems that power the world’s transition to a connected, resilient, and low-carbon future. From offshore and onshore renewable energies to smart cities and homes, Nexans designs and delivers advanced cable solutions, accessories and services that electrify progress safely, efficiently, and sustainably.

With over 140 years of history, through three core businesses: PWR Transmission, PWR Grid, and PWR Connect, Nexans blends deep industry expertise with cutting-edge innovation to accelerate the energy transition and better meet its customers’ needs. Its unique E3 model, focused on Environment, Economy and Engagement, drives every action, aligning performance with purpose.

Nexans operates in 41 countries with 28,500 people and generated €7.1 billion in standard sales in 2024. As recognized climate action leader, Nexans is committed to Net-Zero emissions by 2050 aligned with the Science Based Targets initiative (SBTi) and expanding energy access through the Foundation Nexans.

Nexans is listed on Euronext Paris, Compartment A.
www.nexans.com | #ElectrifyTheFuture

SOURCE Nexans

The wait is almost over. The 2025 ESMO Congress is only days away.

As the global oncology community turns its focus to Berlin, Germany, for the start of the 2025 ESMO Congress on Friday, October 17, the meeting is again primed to deliver practice-changing data across various tumor types and specialties.

With this year’s program shaping up to be one of the most comprehensive yet, OncLive^® is here to help you navigate a crowded agenda featuring key updates and research across the lung, breast, gastrointestinal (GI), genitourinary (GU), gynecologic, and hematologic cancer spaces.

In anticipation of the congress, we gathered insights from experts in their respective fields, and we also invited the oncology community to vote in a series of preview polls highlighting the most-anticipated abstracts and topics in each tumor type.

Before experts from across the field of oncology converge at the 2025 ESMO Congress, there’s still time to prepare and preview some of the biggest presentations and data that shape the next era of oncology care.

Below, take a look at all of our previews for the 2025 ESMO Congress. Be sure to dive in before the congress kicks off on Friday.

Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025

There will be no shortage of anticipated data in the breast cancer space during the 2025 ESMO Congress, with a smattering of late-breaking abstracts and other oral presentations set to dominate the meeting.

“A lot of incredible abstracts and late-breakers will be [presented during] ESMO 2025, [but] there are 2 main categories [of research driving the conversation],” Paolo Tarantino, MD, a research fellow in the Department of Medicine at the Dana-Farber Cancer Institute in Boston, Massachusetts, shared with OncLive. “One, as it often happens, is antibody-drug conjugates [ADCs]. The other hot [topic] is new drugs for hormone receptor–positive breast cancer…[including] CDK 4/6 inhibitors combined with PI3K/mTOR inhibitors.”

Our preview featured insights from Tarantino and the following breast cancer experts:

• Kelly McCann, MD, PhD, an associate clinical professor of medicine in the Division of Hematology/Oncology at the University of California, Los Angeles Health
• Jason A. Mouabbi, MD, an assistant professor in the Department of Medical Breast Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston
• Erika P. Hamilton, MD, director of Breast Cancer Research at Sarah Cannon Research Institute in Nashville, Tennessee

Inside the Most Anticipated Lung Cancer Abstracts at ESMO 2025

“The 2025 ESMO Congress will feature multiple late-breaking abstracts that could reshape the lung cancer treatment landscape,” Amol Akhade, MD, MBBS, a senior consultant at Fortis Hospitals Mumbai, consultant medical oncologist at Suyog Cancer Clinics in Thane, and the honorary in-charge consultant medical oncologist at Topiwala National Medical College in Mumbai, India, told OncLive. “Among them, the [trials] that stand out as particularly important [are the phase 3] HARMONi-6 [NCT05840016] and OptiTROP-Lung04 [NCT05870319] trials, as well as the [the phase 1] Beamion LUNG-1 trial [NCT04886804] and [the phase 1/2] SOHO-01 trial [NCT05099172] in the HER2-mutant setting.”

Along with Akhade, our preview featured expert insights from:

• Sagus Sampath, MD, a radiation oncologist at City of Hope in Duarte, California.
• Balazs Halmos, MD, a professor in the Department of Oncology (Medical Oncology) and Department of Medicine (Oncology and Hematology) and associate director of clinical science at Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York.
• D. Ross Camidge, MD, PhD, a professor in medicine-medical oncology and director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado Cancer Center/Anschutz Medical Campus in Aurora.
• Edward B. Garon, MD, MS, a thoracic medical oncologist and a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California.

Advances in Targeted Therapies and ADCs in Gynecologic Cancer Are Highly Anticipated at ESMO 2025

“[Something] we have to keep track of as we’re hearing the new data is what trials are currently opening up [for enrollment],” Brian Slomovitz, MD, the director of Gynecologic Oncology and cochair of the Cancer Research Committee at Mount Sinai Medical Center in New York, told OncLive. “We have a whole slew of trials opening up in endometrial cancer, about 9 or 10 randomized, phase 3 trials that were opening up…These are all potentially practice-changing trials. We need to really keep an eye on where the data is going and what the new studies are that are coming out that’ll help us do what’s better for our patients.”

Our expert-led gynecologic cancer preview also featured insights from:

• Premal H. Thaker, MD, MS, the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology and director of Gynecological Oncology Clinical Research, and interim chief of the Division of Gynecologic Oncology at Siteman Cancer Center in Saint Louis, Missouri
• Dana M. Chase, MD, a professor of Clinical Obstetrics and Gynecology in the Division of Gynecologic Oncology at the University of California, Los Angeles

ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology

“We’re all looking forward to data with immuno-oncology [IO] and VEGF [inhibitor] combinations that might be coming out,” Kanwal P. S. Raghav, MBBS, MD, a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine, associate vice president of the Department of Ambulatory Medical Operations, and executive medical director of the Department of Ambulatory Treatment Centers at The University of Texas MD Anderson Cancer Center in Houston, told OncLive. “There are data on multiple antibody-drug conjugates with colorectal expansions that are coming forward, [including] data on HER2 and the long-term outcomes for the now FDA-approved fam-trastuzumab deruxtecan-nxki [Enhertu] in CRC. It’s going to be an exciting ESMO.”

Along with Raghav, our exclusive expert preview featured insights from:

• Tanios S. Bekaii-Saab, MD, the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I at the Mayo Clinic College of Medicine and Science, chairman for the Division of Hematology/Medical Oncology at Mayo Clinic, and co-leader of the Advanced Clinical and Translational Science Program and the Disease Group leader for Gastrointestinal Cancers for the Mayo Clinic Cancer Center in Phoenix, Arizona
• Suneel Kamath, MD, an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, as well as a gastrointestinal (GI) medical oncologist at Cleveland Clinic in Ohio

Inside the Most Anticipated Genitourinary Cancer Abstracts at ESMO 2025

“[At the 2025 ESMO Congress,] there will be many exciting abstracts in [GU oncology], so it is difficult to pick just a handful. In the frontline settings, we are in need of novel agents to improve the rate of durable responses. Kidney cancer is still in need of predictive and prognostic biomarkers, and there is much interesting work being done in this space,” David A. Braun, MD, PhD, an assistant professor of medicine (medical oncology) and Louis Goodman and Alfred Gilman Yale Scholar at Yale Medical School in New Haven, Connecticut, explained.

For the GU oncology preview, Braun’s insights were accompanied from perspectives from:

• Alan Tan, MD, an associate professor of medicine, Division of Hematology Oncology at Vanderbilt University Medical Center in Nashville, Tennessee.
• Axel Merseburger, MD, PhD, a professor and chair of the Department of Urology at University Hospital Schleswig-Holstein in Lübeck, Germany.

Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

Although the 2025 ESMO Congress program is driven primarily by data, abstracts, and presentations surrounding solid tumor management, the congress will feature a spread of updates and data emerging from the hematologic oncology landscape.

Read our preview and poll results above to see what hematologic oncology topics made the cut for ESMO 2025 before this field turns its attention to the 2025 ASH Annual Meeting and Exposition in December.

Ratio of high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C) (HDL-C/LDL-C) can be used to predict the prognosis of individuals at high risk for cardiovascular disease (CVD) without type 2 diabetes (T2D), with a ratio between 0.3 and 0.5 being the most helpful range for patients in this population, according to new data published by investigators in Chronic Diseases and Translational Medicine.¹

What is the HDL-C/LDL-C Ratio?

Lipid management is a hallmark of CVD prevention and can improve patient prognosis. Patients with T2D have an especially heightened risk of CVD morbidity and mortality and has been directly linked to lipid metabolism. It is essential to identify more valuable lipid indicators for prognosis improvement and primary prevention.^1,2

Accordingly, studies have affirmed that extremely high HDL-C and excessively low LDL-C can increase the risk of adverse prognoses, highlighting the potential role of the HDL-C/LDL-C ratio as a marker of cholesterol control. Controlling HDL-C/LDL-C ratio can be used to prevent coronary heart disease and stroke, with studies indicating that mortality from such diseases is lowest when HDL-C/LDL-C ratio is between 0.4 and 0.6. Critically, the ratio has been shown to be a more accurate predictor of clinical disease compared with individual lipoprotein levels.^3-5

There is a lack of existing research on the HDL-C/LDL-C ratio, especially in populations at high CVD risk. Furthermore, there is limited data on whether such a ratio could be a reliable prognostic biomarker in populations with high CVD risk who both do and do not have T2D. The current authors aimed to address the association between HDL-C/LDL-C ratio and adverse prognoses in populations at high risk for CVD, while comparing its usefulness between populations with and without T2D.¹

This analysis was based on the Fujian Cardiometabolic Diseases and Comorbidities Cohort trial (NCT06102187), which was an observational study conducted between 2017 and 2021 to assess CVD risk. Associations between HDL-C/LDL-C ratio and all-cause mortality were analyzed using restricted cubic spline curves (RCSs), and the investigators then categorized patients into 3 groups using thresholds of 0.3 and 0.5 for low HDL-C/LDL-C (less than 0.3), middle (HDL-C/LDL-C, between 0.3 and 0.5), and high HDL-C/LDL-C (more than 0.5).¹

What is the Ideal HDL-C/LDL-C Ratio for CVD Prevention?

A total of 32,609 participants were included in the cohort. Based on the RCS analysis, a nonlinear U-shaped relationship between HDL-C/LDL-C and the participants’ all-cause mortality was identified. Compared with the other groups, the RCS analysis indicated that the middle group had the lowest all-cause mortality risk. Kaplan-Meier survival analysis revealed that cumulative all-cause mortality rate was higher in the low and high groups than in the middle group (P < .05), which was verified by a Cox proportional analysis.¹

Additionally, the risk of all-cause mortality (hazard ratio [HR] = 1.40 [95% CI, 1.08—1.82], P < .05 for low; HR = 1.41 [95% CI, 1.15—1.71], P < .01 for high) was greater in the low and high groups than in the middle group in the univariate analysis. When the investigators controlled for covariates, the risk of all-cause mortality (HR = 1.48 [95% CI, 1.14—1.93], P < .01 for low; HR = 1.30 [95% CI, 1.06—1.58], P < .05 for high) was elevated in both groups.¹

The investigators specifically examined associations between HDL-C/LDL-C and all-cause mortality in individuals with and without type 2 diabetes. Kaplan-Meier analyses revealed that the middle group without T2D presented the lowest cumulative all-cause mortality, while no statistically significant differences in all-cause mortality were observed across subgroups in populations at high CVD risk with T2D. Concurrently, Cox proportional hazards regression analysis demonstrated greater risk of all-cause mortality in the low and high ratio groups than in the middle group.¹

Because HDL-C and LDL-C are widely available and simple-to-measure biomarkers, pharmacists and clinicians can easily calculate the ratio necessary to determine patient CVD prognosis. It is critical that the authors noted a range of a ratio of 0.3 to 0.5 was the most beneficial for patients, allowing pharmacists to specifically tailor treatment strategies and help patients reach their goals. Above all, another indicator that can provide early intervention in populations at high CVD risk is critical for primary prevention.¹

“Maintaining HDL-C/LDL-C ratios within the range of 0.3–0.5 may have clinical significance for cohorts without T2D, whereas its prognostic implications in individuals with T2DM necessitate further exploration,” the study authors wrote in their conclusion.¹

REFERENCES

1. Lin B, Ling Y, Zhou G, et al. HDL-C/LDL-C ratio and all-cause mortality in populations at high CVD risk: A prospective observational cohort study. Chronic Dis Transl Med. 2025;11(3):213-223. doi:10.1002/cdt3.70013

2. Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin. Trends Endrocrinol Metab. 2013;24(8):391-397. doi:10.1016/j.tem.2013.04.001

3. You S, Zhong C, Zu J, et al. LDL-C/HDL-C ratio and risk of all-cause mortality in patients with intracerebral hemorrhage. Neurol Res. 2016;38(10):903-908. doi:10.1080/01616412.2016.1204797

4. Zimmer F, Riebeling V, Benke B, Schuster J, Roskamm H. The LDL-HDL ratio in patients with coronary arteriosclerosis. Z Kardiol. 1980;69(3):149-153. PMID: 7456590. https://pubmed.ncbi.nlm.nih.gov/7456590/

5. Sun T, Chen M, Shen H, et al. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease. BMC Cardio Disord. 2022;22(273). doi:10.1186/s12872-022-02706-6

6. Cohort study in Fuijan province. ClinicalTrials.gov Identifier: NCT06102187. Last Updated November 3, 2023. Accessed October 13, 2025. https://clinicaltrials.gov/study/NCT06102187